What Are Wall Street Analysts' Target Price for IQVIA Holdings Stock?

Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides healthcare research services. Valued at $32.6 billion by market cap, the company offers analytics, technology solutions, and clinical research services to the life sciences industry, which helps them in the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.

Shares of this contract research gianthave considerably underperformed the broader market over the past year. IQV has declined 24.9% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 13.3%. In 2025, IQV’s stock fell 5.7%, compared to the SPX’s 8.3% rise on a YTD basis.

More News from Barchart

Should You Buy the Dip as Palantir Stock Falls for 7 Straight Days? George Soros Is Betting Big on Beaten-Down UnitedHealth Stock. Should You? 2 ‘Strong Buy’ Stocks Offering Fat Yields of Over 7.5% in August 2025 Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.

Narrowing the focus, IQV’s underperformance is also apparent compared to the Health Care Select Sector SPDR Fund (XLV). The exchange-traded fund has declined about 11.4% over the past year. Moreover, the ETF’s marginal losses on a YTD basis outshine the stock’s single-digit dip over the same time frame.www.barchart.com

On Jul. 22, IQV shares surged 17.9% after reporting its Q2 results. Its adjusted EPS of $2.81 surpassed Wall Street expectations of $2.76. The company’s revenue was $4.02 billion, exceeding Wall Street forecasts of $3.96 billion. IQV expects full-year adjusted EPS in the range of $11.75 to $12.05, and expects revenue in the range of $16.1 billion to $16.3 billion.

For the current fiscal year, ending in December, analysts expect IQV’s EPS to grow 4.8% to $10.74 on a diluted basis. The company’s earnings surprise history is mixed. It beat the consensus estimate in three of the last four quarters while missing the forecast on another occasion.

Among the 22 analysts covering IQV stock, the consensus is a “Strong Buy.” That’s based on 15 “Strong Buy” ratings, one “Moderate Buy,” and six “Holds.”www.barchart.com

The configuration has been consistent over the past three months.

On Aug. 12, Barclays PLC (BCS) analyst Luke Sergott maintained a “Hold” rating on IQV and set a price target of $185.

The mean price target of $214.19 represents a 15.5% premium to IQV’s current price levels. The Street-high price target of $250 suggests an ambitious upside potential of 34.9%.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

View Comments